Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health announced Nader Kabbani will join the telehealth company as its new chief operations officer. Kabbani ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.

Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.